Basal Cell Nevus Syndrome
Basal cell nevus syndrome (BCNS), also known in the literature as Gorlin-Goltz syndrome or nevoid basal cell carcinoma syndrome (NBCCS), is a rare autosomal dominant genetic disorder caused by mutations in the PTCH1 gene (or, less often, SUFU or PTCH2). It is marked by numerous basal cell carcinomas (BCCs) starting at a very young age, together with problems in several body systems: odontogenic keratocysts (OKCs) of the jaw, palmar and plantar pits, calcification of the falx cerebri, skeletal anomalies (such as bifid ribs) and a higher risk of internal tumors such as medulloblastoma.
At Haute-Derma, we manage BCNS with a layered, specialist plan: molecular genetic screening, whole-body surveillance to international standards, and a flexible combination of tissue-sparing micrographic surgery, immunomodulating therapy and Hedgehog pathway–targeted therapy. This approach keeps invasive operations to a minimum, treats BCCs early and protects patients’ long-term quality of life.
Clinical Features and Pathology in Depth
Pathogenesis and Genetic Mutations
- The Hedgehog signaling pathway: Inactivating mutations in PTCH1 (on chromosome 9q22.3) remove the normal brake on the Smoothened (SMO) protein. The Hedgehog pathway then stays switched on, driving proliferation of epidermal progenitor cells and producing anywhere from dozens to thousands of BCCs over a lifetime.
- Clinical diagnostic criteria (Evans/Genoese criteria): BCNS is diagnosed when a patient meets 2 major criteria, or 1 major plus 2 minor criteria:
| Major Criteria | Minor Criteria |
|---|---|
| • More than 2 BCCs, or 1 BCC before age 20. | • Skeletal anomalies: bifid rib, wedge-shaped vertebrae, short fingers. |
| • Odontogenic keratocyst (OKC) confirmed by histology. | • Macrocephaly, frontal bossing, widely spaced eyes (hypertelorism). |
| • Palmar/plantar pits (≥ 3 pits). | • Radiologic findings: widened shoulder joint spaces, high-arched palate. |
| • Calcification of the falx cerebri on X-ray/CT. | • Ovarian fibroma or cardiac fibroma. |
| • First-degree relative with BCNS. | • Medulloblastoma in childhood. |
Histopathology
- BCC in BCNS: Under the microscope, BCCs in BCNS look structurally the same as sporadic BCCs: lobules of basaloid cells with peripheral palisading and stromal retraction. What sets them apart is how numerous they are, their onset in adolescence and their frequently multicentric pattern.
- Odontogenic keratocyst (OKC): The cyst is lined by a thin keratinizing squamous epithelium (6–8 cell layers) with a corrugated parakeratinized surface, a distinctly palisaded basal layer and no rete ridges. It is filled with dense keratin and recurs very often after enucleation.
Differential Diagnosis and Immunohistochemistry (IHC)
| Condition | Distinguishing Clinical/Histologic Features | IHC and Genetic Markers |
|---|---|---|
| BCNS (Gorlin syndrome) | Multiple BCCs from childhood, palmar pits, jaw OKCs, PTCH1 mutation. | BerEP4 (+) in BCCs; genetic testing confirms a PTCH1/SUFU mutation. |
| Bazex-Dupré-Christol syndrome | Multiple BCCs, ice-pick follicular atrophoderma on the backs of the hands, hypotrichosis. | X-linked dominant (Xq25); no jaw cysts or palmar pits. |
| Rombo syndrome | Multiple BCCs, facial telangiectasia, follicular atrophy, milia. | Autosomal dominant; BCCs start later (in adulthood). |
| Xeroderma pigmentosum (XP) | Multiple BCCs, SCCs and melanomas due to extreme sun sensitivity; marked pigmentary changes. | Mutations in DNA repair genes (XPA–XPG); no skeletal anomalies or OKCs. |
Our Approach to Basal Cell Nevus Syndrome
Haute-Derma manages BCNS with a modern model that brings together genetic medicine and minimally invasive treatment:
- Genetic screening and whole-body lesion mapping: Gene sequencing for PTCH1/SUFU mutations and a digital photographic record (total body photography) to track every BCC over time.
- Tissue-sparing surgery: We avoid unnecessary wide excisions to spare young patients the psychological burden and the contracted facial scars they can leave.
- Field and targeted therapy combined: Topical immunomodulators, Mohs micrographic surgery and oral Hedgehog pathway inhibitors for patients with multiple progressing lesions.
- Radiation avoidance and secondary protection: Radiotherapy is contraindicated, because radiation can trigger a crop of new BCCs in the treated area.
How We Diagnose Basal Cell Nevus Syndrome at Haute-Derma
To make an accurate diagnosis of BCNS and screen for complications in other organs, Haute-Derma follows a standard four-step process:
- Clinical examination and full-body dermoscopy: We assess every pearly papule or nodule suspicious for BCC, check the palms and soles for pits and note characteristic facial features.
- Multisystem imaging: A panoramic jaw X-ray (to look for OKCs), a lateral skull X-ray (for falx calcification) and a chest X-ray (for bifid ribs).
- Confirmatory biopsy: Punch biopsies of representative papules confirm BCC and show its histologic subtype.
- Molecular genetic testing: Next-generation sequencing (NGS) detects mutations in PTCH1 or SUFU and supports genetic counseling for the next generation.
How Basal Cell Nevus Syndrome Is Treated at Haute-Derma
Treatment at Haute-Derma aims to keep the number of BCCs under control, preserve appearance and manage complications in other organs:
- Mohs micrographic surgery (MMS):
- Our first choice for large BCCs, tumors in high-risk sites (the H-zone of the face) and those with an aggressive (infiltrative/morpheaform) growth pattern.
- Examines 100% of the microscopic margin, clearing the cancer completely while sparing as much healthy tissue as possible.
- Minimally invasive local treatments:
- Ultrapulse CO2 laser ablation / curettage and electrodesiccation: For dozens of superficial or small nodular BCCs (< 2–3 mm) on the trunk, removing lesions quickly with minimal scarring.
- Intensive topical therapy (imiquimod 5% / 5-FU): Field treatment for scattered superficial BCCs.
- Systemic targeted therapy (Hedgehog pathway inhibitors: vismodegib/sonidegib):
- For patients with dozens to hundreds of BCCs that cannot be controlled with conventional surgery.
- These drugs shrink existing tumors and markedly reduce the number of new BCCs.
- Multidisciplinary care and aesthetic recovery:
- Referral to oral and maxillofacial surgery for definitive treatment of jaw OKCs (enucleation combined with Carnoy’s solution to reduce recurrence).
- LED light therapy to support skin recovery, plus guidance on strict broad-spectrum sun protection.
